EU approves Lynparza to treat Ovarian Cancer- AstraZeneca
AstraZeneca announced that the European Commission (EC) has granted Marketing Authorisation for Lynparza (olaparib) capsules (400mg twice daily) as the first therapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer who are in complete response or partial response to platinum-based chemotherapy.
Olaparib is a poly ADP-ribose polymerase (PARP) inhibitor that exploits tumour DNA repair pathway deficiencies to preferentially kill cancer cells. It is the first PARP inhibitor to be approved for patients with platinum-sensitive relapsed BRCA-mutated Ovarian Cancer. Patients will be identified through a validated diagnostic test.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.